46 results on '"Vanoli, Fiammetta"'
Search Results
2. Comparison of quantitative muscle ultrasound and whole-body muscle MRI in facioscapulohumeral muscular dystrophy type 1 patients
3. Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies
4. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
5. Current drug treatment of myasthenia gravis
6. High-resolution ultrasound of peripheral nerves in late-onset hereditary transthyretin amyloidosis with polyneuropathy: similarities and differences with CIDP
7. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management
8. Nerve high-resolution ultrasound in a 2-year follow-up of radial nerve palsy related to humeral shaft fractures.
9. Skin biopsy and quantitative sensory assessment in an Italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation
10. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
11. Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up
12. Nerve high-resolution ultrasonography in peripheral nerve injuries associated with supracondylar humeral fractures in children
13. Efgartigimod in generalized myasthenia gravis: A real‐life experience at a national reference center
14. Nerve ultrasonography findings as possible pitfall in differential diagnosis between hereditary transthyretin amyloidosis with polyneuropathy and chronic inflammatory demyelinating polyneuropathy
15. Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports
16. Efgartigimod improves triple-negative myasthenia gravis
17. A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal ECG at baseline at an Italian clinical centre
18. Concordance between patient‐ and physician‐reported Myasthenia Gravis Activities of Daily Living (MG‐ADL) scores
19. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
20. Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis
21. Ravulizumab for the treatment of myasthenia gravis
22. Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores
23. Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis
24. Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies
25. What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?
26. miRNA in spinal muscular atrophy pathogenesis and therapy
27. Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy
28. Nerve high-resolution ultrasound in a 2-years follow-up of radial nerve palsy related to humeral shaft fractures
29. Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
30. High-resolution ultrasound of peripheral nerves in late-onset hereditary transthyretin amyloidosis with polyneuropathy: similarities and differences with CIDP
31. Clinical and molecular features and therapeutic perspectives of spinal muscular atrophy with respiratory distress type 1
32. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
33. Skin biopsy and quantitative sensory assessment in an Italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation
34. Complement Inhibition for the Treatment of Myasthenia Gravis
35. Efgartigimod: A First-in-class Investigational Antibody Fragment for the Treatment of Generalized Myasthenia Gravis.
36. Complement Inhibition for the Treatment of Myasthenia Gravis
37. Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of myasthenia-myositis association from a large cohort of patients
38. Novel ACTA1 mutation causes late-presenting nemaline myopathy with unusual dark cores
39. Gender effect on cardiac involvement in myotonic dystrophy type 1
40. ATTRv amyloidosis Italian Registry: clinical and epidemiological data
41. Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients
42. Nerve high‐resolution ultrasonography in tangier disease
43. Widening the phenotypical spectrum of EGR2-related CMT: Unusual phenotype for R409W mutation
44. Gender effect on cardiac involvement in myotonic dystrophy type 1.
45. miRNA in spinal muscular atrophy pathogenesis and therapy
46. Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.